4/06/2013. Medication Observation POAG. Proportion. Native American 0.1% 0.4%
|
|
- Rolf Mosley
- 5 years ago
- Views:
Transcription
1 Clinical Research in Glaucoma: Putting Science into Practice J. James Thimons, O.D., FAAO Chairman, National Glaucoma Society Ocular Hypertension Treatment Study (OHTS) Primary Goals Evaluate the safety and efficacy of topical ocular hypotensive medication in delaying or preventing the development of POAG in individuals with elevated IOP Identify baseline demographic and clinical factors that predict which participants will develop POAG The OHTS Exclusion Criteria VA worse than /40 in either eye Previous intraocular surgery other than uncomplicated CE with PCIOL Diabetic retinopathy Other disease capable of causing VF loss/ ON damage Baseline Characteristics by Randomization Group Self-designated Race Primary POAG Endpoints* Log Rank P-value <0.001, Hazard Ratio 0.40, 95% CI (0.27, 0.59) 0.15 Medication Observation Medication n=817 Observation n=819 Native American 0.1% 0.4% Asian 05% 0.5% 12% 1.2% African American 25.0% 25.0% Hispanic 2.9% 4.3% Caucasian 70.6% 68.4% Proportion POAG At 5 yrs, 4.4% of treated group and 9.5% observation group developed glaucoma Other 1.0% 0.7% Months *through 8 Nov 01 1
2 First POAG Endpoint (n=125) 10% 55% 35% Optic Disc VF Defect Concurrent VF and ON defect Includes all subjects in medication and observation group Treatment perhaps less protective in African Americans African Americans 12.7% POAG endpoints in observation group 69% 6.9% POAG endpoints in medication group Hazard Ratio 0.54 P value for interaction 0.26 Others 10.2% POAG endpoints in observation group 3.6% POAG endpoints in medication group Hazard Ratio 0.34 Significant Baseline Factors Predicting Progression to POAG Univariate Analysis Age Black race Male gender Heart disease Increased IOP Thinner CCT Greater PSD Horizontal C/D ratio Vertical C/D ratio Multivariate Analysis Age IOP CCT PSD Vertical C/D ratio POAG Endpoints by Central Corneal Thickness and Baseline IOP (mmhg) in Observation Group* Baseline IOP (mmhg) < >25.75 >23.75 to < % 13% 6% 12% 10% 7% 17% 9% 2% < 555 >555 to < 588 >588 Central Corneal Thickness (microns) POAG Endpoints by Central Corneal Thickness and Baseline Vertical C/D Ratio in Observation Group* Vertical C/D Ratio < 0.30 >0.50 >0.30 to < % % 8% 26% % 4% 15% 1% 4% < 555 >555 to < 588 >588 Central Corneal Thickness (microns) CCT vs IOP AJO 1997/ Wolfs RC et al. 395 subjects 352 controls 13 OHTN 30 COAg CCT Controls OHTN- microns thicker COAG 21 microns thinner 2
3 CCT vs Advanced Glaucoma Arch Ophth 04 / Herndon LW 350 eyes/190 patients age, sex, race, fam Hx, # meds, IOP, CCT, VF AA s 537 microns/ Whites 556 microns Lower CCT - increased risk of AGIS Increased C/D Increased MD Increased # COAG meds Peak IOP Outside Office Hours PURPOSE: To determine the relationship between office IOP and peak IOP METHODS (Study One) 1 : 42 patients with OAG Treated with 3 different IOP lowering eye drops 24 hr IOP values obtained in sitting position with Goldmann applanation tomography at 3 hr intervals METHODS (Study Two) 2 : 103 patients with OAG (including 35 untreated) 24 hr IOP values obtained at 2 hr intervals using a pneumatometer, in sitting and supine positions during the diurnal/wake period and in the supine position during the nocturnal/sleep period 1.Nakakura S, et al. J Glaucoma 07; (2): Mosaed S, et al. Am J Ophthalmol. 05; 139: Peak IOP Outside Office Hours IOP is Higher at Night of eyes Number o Study 1 Times at which maximum and minimum IOP occurred in a 24- hr period 1 : 40 3am 6am 28 9am 12pm pm 6pm pm 12am Time of minimum IOP in 24 hour Time of maximum IOP in 24 hour Study 2 67% of peak IOP occurs outside office hours 2 PURPOSE: To characterize the 24 hr pattern of IOP in untreated patients METHODS: 24 untreated patients with newly diagnosed glaucomatous optic discs and/or abnormal visual fields 24 hr IOP values obtained with a penumatonometer at 2 hr intervals, in the sitting and supine position during the diurnal/wake period and in the supine position during the nocturnal/sleep period 1.Nakakura S, et al. J Glaucoma 07; (2): Mosaed S, et al. Am J Ophthalmol. 05; 139: Liu JH et al. Invest Ophthalmol Vis Sci. 03; 44: IOP is Higher at Night Higher nocturnal supine IOP than diurnal sitting IOP (healthy and OAG) Supine IOP higher than sitting IOP, regardless of time of day Habitual IOP of healthy eyes Habitual IOP of glaucomatous eyes Diurnal Sitting Nocturn Diurnal Diurnal Sitting Noctur Diurnal al Sitting nal Sitting Supine 26 Supine 26 n= n= IOP (mm Hg) :30 PM 5:30 PM 7:30 PM 9:30 PM 11:30 PM 1:30 AM 3:30 AM 5:30 AM 7:30 AM Clock Time Liu JH et al. Invest Ophthalmol Vis Sci. 03; 44: :30 AM 11:30 AM 1:30 PM IOP (mm Hg g) 15 3:30 PM 5:30 PM 7:30 PM 9:30 PM 11:30 PM 1:30 AM 3:30 AM 5:30 AM 7:30 AM Clock Time *Error bars = SEM 9:30 AM 11:30 AM 1:30 PM Collaborative Normal Tension Methods One eye per each of 5 subjects with NTG was randomized either to 30% IOP reduction or to no treatment (control) Randomization criteria included documented progression of field defects, new disc hemorrhage, or field defects that threatened fixation 17 3
4 Collaborative Normal Tension Treatment for IOP reduction: medication (excluding beta- blockers or alpha2 adrenal receptor agonists due to concerns of vasoactivity), ALT, or filtration surgery Collaborative Normal Tension Survival analysis: time to visual field progression Findings At 5 years, treated patients showed overall survival of 80% compared with 40% in controls (P=.0018) The beneficial results of IOP reduction were found only when the impact of cataracts on visual field progression (caused mainly by filtration surgery) was removed The Collaborative Normal-Tension Clinical Pearls 1. Therapeutic intervention (30% IOP reduction) helped prevent visual field progression. However, one must adjust for the development of cataracts, which occur commonly after filtration surgery, to detect the therapeutic benefit of IOP reduction. The Collaborative Normal- Tension Clinical Pearls 2. 30% IOP reduction was achieved in 57% of patients receiving medical therapy with or without argon laser trabeculoplasty (ALT), which underscores the importance of conservative therapy. Since beta- blockers, alpha2 agonists, and prostaglandin analogs were not used in the study, currently available medical agents may achieve IOP reduction in a greater percentage of patients. The Collaborative Normal-Tension Clinical Pearls 3. Approximately 50% of eyes without a history of progression did not progress by 7 years when untreated. However, if progression has been documented in the past, future progression is highly likely, and IOP reduction is recommended. The Collaborative Normal-Tension Clinical Pearls 4. Confirmatory visual fields are essential for verifying suspected progression. For both visual function as well as structural tests, it is important to confirm suspected progression. 4
5 The Collaborative Normal-Tension Clinical Pearls 5. Disc hemorrhage is a strong, negative prognostic sign; other risk factors include migraine and female gender. Diurnal Fluctuations in IOP: Independent Risk Factor? PURPOSE: To study the risk associated with diurnal IOP variations in patients with OAG METHODS: 64 patients with OAG and IOP below 25 mm Hg (over 5 year follow up) Patients successfully performed tonometry with a self tonometer 5 times a day for 5 days Baseline status and time to progression of visual field loss identified from clinical charts Level and variability of diurnal IOP characterized and risk of progression analyzed using a nonparametric time to event model Asrani S, et al. J Glaucoma 00; 9: Diurnal Fluctuations Correlate with Visual Field Progression risk of disease on within 5 years Relative progressio Diurnal IOP range 3.1 mm Hg 5.76 Diurnal IOP range 5.4 mm Hg Habitual IO OP (mm Hg) Timolol: Nocturnal IOP N=18 Error bars = SEM Sitting Supine Sitting No treatment Timolol Hazard ratio between higher quartile and lower quartile for Range in Home IOP was PM 5.30PM 7.30PM 9.30PM 11.30PM 1.30AM 3.30AM 5.30AM Clock Time 7.30AM 9.30AM 11.30AM 1.30PM Asrani S, et al. J Glaucoma 00; 9: Liu JH, et al. Am J Ophthalmol. 04; 138: tual IOP (mmhg) Habit Effect of PGA s on Diurnal and Nocturnal IOP DIURNAL/WAKE 3:30 PM 5:30 PM 7:30 PM 9:30 PM 11:30 PM Baseline NOCTURNAL/SLE EP Sit AJ, et al. Am J Ophthalmol. 06; 1(6): DIURNAL/WAKE 1:30 AM 3:30 AM 5:30 AM 7:30 AM 9:30 AM 11:30 AM 1:30 PM Clock Time On Treatment Error bars = SEM Measured in the usual habitual position of the patients during those time periods Diurnal period sitting Nocturnal period supine Early Manifest Glaucoma Trial Compared the effect of immediately lowering the IOP vs no treatment or later treatment, on the progression of newly detected open-angle glaucoma Heijl A. et al. Arch Ophthalmol. 02;1:
6 EMGT Participants 255 open angle glaucoma patients Ages (median 68 years) Early glaucoma Mild VF loss (median MD, 4dB) Median IOP of EMGT Excluded from trial Patients with IOP greater than 30 mmhg Patients with advanced VF loss Heijl A. et al. Arch Ophthalmol. 02;1: Heijl A. et al. Arch Ophthalmol. 02;1: EMGT - Interventions Subjects randomized to either Argon Trabeculoplasty + Betaxolol (n=129) OR No initial treatment (n=126) HVF 30-2 and IOP q 3 months for 10 years Optic nerve photos every 6 months Heijl A. et al. Arch Ophthalmol. 02;1: EMGT- Results 53 % of subjects progressed Progression 45 % of treated patients progressed (58/129) 62% of untreated patients progressed (78/126) Statistically significant (P=.007) This progression difference was evident at 11 months and increased steadily over time Leske MC et al. Arch Ophthalmol. 03 Jan;121(1): EMGT- Results In multivariate analyses, progression risk was halved by treatment Progression risk decreased by about 10% with each mm of HG of IOP reduction from baseline to the first follow-up visit Progression risk increased by about 10 % with each mm of HG of IOP increase from baseline at first follow-up visit Leske MC et al. Arch Ophthalmol. 03 Jan;121(1): EMGT- Summary Factors Increasing Risk of Progression Higher baseline IOP Exfoliation Bilateral disease Older age Worse MD on visual field Presence of disc hemorrhage Leske MC et al. Arch Ophthalmol. 03 Jan;121(1):
7 Collaborative Initial Glaucoma Treatment Study On ongoing study to determine if newly diagnosed open-angle glaucoma is better treated with initial medical therapy or immediate filtration surgery Different study design: Patient satisfaction and quality of life are determining factors in deciding patient care; enrolled patients interviewed before being assigned treatment then re- interviewed every 3-6 months Allows referring ophthals to remain primary caretaker; routine biannual visits conducted at clinical center CIGTS: Subjects Eligibility criteria years old Newly diagnosed glaucoma as determined by elevated IOP, glaucomatous optic disc damage and VF loss Must not have received any previous glaucoma treatment for longer than days CIGTS: Subjects 607 patients enrolled at centers Of the 607 patients enrolled: 90.6% had primary open angle glaucoma 4.6% pigmentary pg yg glaucoma 4.8% pseudoexfoliative glaucoma Subjects randomized to surgery or stepped medical therapy CIGTS: Subjects Medications: typically BB followed in order by other monotherapy, dual therapy, triple therapy, quad therapy, ALT, Trab, meds, trab+mmc, meds Surgical treatment arm: patients underwent immediate trab and, with documented failure, proceed to ALT, then conclude with medications CIGTS: Results Quality of life: Surgical vs. Medical The medical group reported a variety of systemic symptoms that were not consistent ste t over time, but were e clearly different from the symptoms reported by the surgical group CIGTS: Results Clinical Results: Surgery vs. Medicine Average pressure in the medically treated group mmhg Pressure in the surgical group was 3 points lower (-15) 15) Ophthalmology 01; 108: Ophthalmology 01; 108:
8 CIGTS: Results Clinical Results: Surgery vs. Medicine VF loss did not differ over 5 years between treatment groups VA was better for medically treated group over much of the study, but by 4 years, was no different than the surgical group Number progressing in both groups was low (15%) Ophthalmology 01; 108: CIGTS: Results Clinical Results: Surgery vs. Medicine THREE TIMES THE RATE of cataract in the surgical group Glaucoma Laser Trial 271 patients with previously untreated primary open angle glaucoma randomized to ALT or medication (Timolol) Through 2-year follow-up, ALT eyes had lower intraocular pressure (IOP) than medication-treated treated eyes; 25% did not require Rx At 7 years, in 3 of the original 271 patients, ALT-treated eyes had lower IOP, better visual field, and optic disc status than eyes in the medication group Glaucoma Laser Trial Glaucoma Laser Trial (GLT) Followed 3 patients 7 years randomized one eye to ALT and one eye to Timolol 0.5% twice daily ALT eye: 1.2mm Hg greater reduction in IOP 0.6 db better visual field slightly less optic nerve cupping (-0.01) Glaucoma Laser Trial Research Group, AJO Glaucoma Laser Trial (GLT) Results: Selective Laser Trabeculoplasty (SLT) Eyes treated initially with ALT had lower IOP (1.2 mmhg) and better VF and optic disc status ALT was as efficacious as medications in controlling pressure and preserving optic disc function 8
9 Selective Laser Trabeculoplasty Results comparable to ALT (argon laser trab.) 50 spots to nasal trabecular meshwork Less traumatic than ALT 70% of pts respond IOP reduced by > 3 mmhg, mean 23.5% ALT SLT SLT Effectivity International studies show IOP reductions of 22%-28% 28% with weeks follow-up In a prospective, randomized clinical trial, SLT and ALT were shown to have a similar effect on IOP reduction 85% Success on initial treatment 1-5 years of IOP control if initial success Glaucoma & Pregnancy BJO 09; JD Ho: 244 pregnant women treated for glaucoma analyzed for birth weight 1,952 age matched controls No significant difference between women on BB s vs: no Tx Herndon, L: D/C Brimonodine several weeks before d/t risk of apnea AGIS Patients enrolled patients 789 eyes 8 years of follow up Randomized to ALT or Trab first for COAG patients inadequately controlled with meds Main result: no difference between the two groups AGIS How effective is IOP lowering in preserving VF? Is there an ideal IOP that provides maximum benefit in reducing or eliminating pressure-related related component of damage? 9
10 defect score Mean change in visual d AGIS 7 Sustained IOP below 18 mm Hg: Positive Correlation with Stability of Visual Field 5 Percent of Visits with IOP Less Than 18 mm Hg 4 100% of visits % of visits it % of visits % of visits Follow-up (years) AGIS Investigators, 00, Am. J. Ophthalmol., 130, AGIS 7 Report Patients with IOP<18 on 100% of follow-up exams over 6 years had mean change from baseline VF close to ZERO. (Mean IOP=12.3 over 6 years) Patients with IOP<18 on 50% of follow-up exams showed progression Am J Ophthalmol 00;130: A message from AGIS and CIGTS Endoscopic CycloPhotocoagulation Aggressive IOP-lowering by any means is the best way to protect against further VF loss E2 Applications Ocular Endoscopy ECP Treatment Limbal Approach Posterior to Iris Zonules Dropped IOL Peripheral Retina 10
11 Incision Placement: Straight Endoscope Incision Size: Use at least a 2.6mm Keratome blade for ease of insertion to prevent corneal torquing. ECP Treatment Limbal Approach P L ECP for Refractory Glaucoma s Studies Alvarado et all AJO % patients with refractory glaucoma 35% avg drop in IOP 33% drop in medications 90% has IOP 21mm Hg Lima et all J of Glauc patients with refractory glaucoma 24 month follow up Randomized to ECP vs Ahmed Valve 73% success in both groups 2.9% choroidal effusion in ECP group 18% choroidal effusion and flat AC in Ahmed Group Hint: Surgeon s chair may be repositioned as needed. Studies Table 13 mmhg 19 Phaco-ECP vs Phaco Alone: Mean IOP Over Time 1.53 Meds Phaco-ECP Phaco Alone 1. Meds Meds Meds 15 Pre-Op 6 Months 1 Year 2 Years 3 Years Phaco-ECP Phaco Alone
Clinical Research in Glaucoma
Clinical Research in Glaucoma J. James Thimons, O.D., FAAO Chairman, National Glaucoma Society www.nationalglaucomasociety.org Ocular Hypertension Treatment Study (OHTS) Primary Goals Evaluate the safety
More informationOcular Hypotensive Efficacy of Netarsudil Ophthalmic Solution 0.02% Over a 24-Hour Period: A Pilot Study
Ocular Hypotensive Efficacy of Netarsudil Ophthalmic Solution 0.02% Over a 24-Hour Period: A Pilot Study James H. Peace, M.D. 1, Casey K. Kopczynski, Ph.D. 2, and Theresa Heah, M.D. 2 1 Inglewood, CA 2
More informationPresent relevant clinical findings of four landmark glaucoma trials OHTS, EMGT, CNTGS and CIGTS.
Course title: The Glaucoma Compass Course length: 1 hour +/- 31 slides Corse Description: Even with the technology and available information, glaucoma decision making can still be confusing. How should
More informationLandmark Glaucoma Studies
Landmark Glaucoma Studies: How They Affect Our Management Strategies Today Disclosures None By: Alex Kabiri, O.D. & Devin Singh, O.D. Course Goals 1. Review series of glaucoma studies that: Evaluate when
More informationRole of Central Corneal Thickness in Circadian Intraocular Pressure Fluctuations among Patients with Primary Open Angle Glaucoma
Role of Central Corneal Thickness in Circadian Intraocular Pressure Fluctuations among Patients with Primary Open Angle Glaucoma Mohannad Albdour MD*, Karanjit Kooner MD, PHD** ABSTRACT Objectives: To
More informationPractical approach to medical management of glaucoma DR. RATHINI LILIAN DAVID
Practical approach to medical management of glaucoma DR. RATHINI LILIAN DAVID Glaucoma is one of the major causes of visual loss worldwide. The philosophy of glaucoma management is to preserve the visual
More informationCollaboration in the care of glaucoma patients and glaucoma suspects. Barry Emara MD FRCS(C) Nico Ristorante November 29, 2012
Collaboration in the care of glaucoma patients and glaucoma suspects Barry Emara MD FRCS(C) Nico Ristorante November 29, 2012 Goals of Collaboration Patient-centred and evidence based approach Timely access
More informationGlaucoma: NOT just IOP, Think DPP, OMG!
Glaucoma: NOT just IOP, Think DPP, OMG! Bruce E. Onofrey, OD, RPh, FAAO Professor, Univ. Houston Exec. Director Continuing Education Programs I m a clinician, so let s talk patients TWO Patients ( a priest
More informationGlaucoma Disease Progression Role of Intra Ocular Pressure. Is Good Enough, Low Enough?
Glaucoma Disease Progression Role of Intra Ocular Pressure Is Good Enough, Low Enough? Glaucoma Diseases Progression Key Considerations Good number of patients may be diagnosed only after some damage the
More information53 year old woman attends your practice for routine exam. She has no past medical history or family history of note.
Case 1 Normal Tension Glaucoma 53 year old woman attends your practice for routine exam. She has no past medical history or family history of note. Table 1. Right Eye Left Eye Visual acuity 6/6 6/6 Ishihara
More informationLong Term Efficacy of Repeat Treatment with SLT: Seven Years Follow up
Long Term Efficacy of Repeat Treatment with SLT: Seven Years Follow up Lawrence F. Jindra, MD Columbia University Winthrop University Hospital Disclosure Speaker has independently conducted and financed
More informationIntro to Glaucoma/2006
Intro to Glaucoma/2006 Managing Patients with Glaucoma is Exciting Interesting Challenging But can often be frustrating! Clinical Challenges To identify patients with risk factors for possible glaucoma.
More informationBehandlungsstrategien beim Offenwinkelglaukom. F. Bochmann, Augenklinik LUKS
Behandlungsstrategien beim Offenwinkelglaukom F. Bochmann, Augenklinik LUKS What is strategy? what is our goal? where are we? how can we achieve our goal? Mission Statement The goal of glaucoma management
More information9/6/2013. Evidence Based Guidance on Glaucoma Laser Trabeculoplasty and Early Surgery. Simon K. Law, MD. Clinical Professor of Health Sciences
Evidence Based Guidance on Glaucoma Laser Trabeculoplasty and Early Surgery Simon K. Law, MD Clinical Professor of Health Sciences 25.5 mmhg 24 mmhg 1 Additional Opinions. First ophthalmologist diagnosed
More informationIs NTG different from POAG?
Is NTG different from POAG? Sunita Radhakrishnan, M.D Glaucoma Center of San Francisco Glaucoma Research and Education Group Subset of POAG 1 Connective tissue structure within ONH Ganglion cell susceptibility
More informationFluctuation of Intraocular Pressure and Glaucoma Progression in the Early Manifest Glaucoma Trial
Fluctuation of Intraocular Pressure and Glaucoma Progression in the Early Manifest Glaucoma Trial Boel Bengtsson, PhD, 1 M. Cristina Leske, MD, MPH, 2 Leslie Hyman, PhD, 2 Anders Heijl, MD, PhD, 1 Early
More informationEarly Detection Of Glaucoma Clinical Clues. Points To Live By. Glaucoma Risk Factors 10/3/2014
Early Detection Of Glaucoma Clinical Clues Eric E. Schmidt, O.D. Omni Eye Specialists Wilmington, NC schmidtyvision@msn.com Points To Live By 25% of G pxs NEVER have IOP >21mm 50% of G pxs have trough
More informationKey Findings and Treatment Lessons By Annie Stuart, Contributing Writer
Landmark Glaucoma Studies Key Findings and Treatment Lessons By Annie Stuart, Contributing Writer illustration: alfred t. kamajian. photo: jason s. calhoun, mayo clinic, jacksonville, fla. In the past
More informationEffect of brimonidine on intraocular pressure in normal tension glaucoma: A short term clinical trial
European Journal of Ophthalmology / Vol. 13 no. 7, 2003 / pp. 611-615 Effect of brimonidine on intraocular pressure in normal tension glaucoma: A short term clinical trial S.A. GANDOLFI, L. CIMINO, P.
More informationManaging the Patient with POAG
Managing the Patient with POAG Vision Institute Annual Fall Conference Mitchell W. Dul, OD, MS, FAAO mdul@sunyopt.edu Richard J. Madonna, MA, OD, FAAO rmadonna@sunyopt.edu Ocular Hypertension (OHT) Most
More informationMEDICAL POLICY SUBJECT: CORNEAL ULTRASOUND PACHYMETRY. POLICY NUMBER: CATEGORY: Technology Assessment
MEDICAL POLICY SUBJECT: CORNEAL ULTRASOUND,, PAGE: 1 OF: 5 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product, including
More information3/31/2019. Role of IOP. Role of IOP. Role of IOP. Role of IOP. Evaluation of glaucoma has changed Why hasn t treatment?
Glaucoma Update ROLE FOR RHOPRESSA Gregory D. Searcy, M.D. 1857: German ophthalmologist Albrecht Van Graefe concluded all glaucomatous optic disc excavation is associated with high IOP based on the only
More information7/25/2018 GLAUCOMA: YOU MAKE THE CALL GLAUCOMA: YOU MAKE THE CALL. Please text us your questions! PACHYMETRY
GLAUCOMA: YOU MAKE THE CALL Lori Vollmer, OD Jessica Steen, OD Greg Caldwell, OD Joseph Sowka, OD GLAUCOMA: YOU MAKE THE CALL Please text us your questions! Joe: 954-298-0970 Greg: 814-931-2030 PACHYMETRY
More informationOne-year Results of a Schlemm s Canal Microstent for IOP Reduction in Open Angle Glaucoma
One-year Results of a Schlemm s Canal Microstent for IOP Reduction in Open Angle Glaucoma Thomas W. Samuelson, MD Minnesota Eye Consultants On Behalf of the HYDRUS I Investigators 1 Disclosures This study
More informationA Review Of Risk Factors. Early Detection Of Glaucoma Clinical Clues. A risk factor analysis is critical. Points To Live By
A Review Of Risk Factors Early Detection Of Glaucoma Clinical Clues Eric E. Schmidt, O.D. Omni Eye Specialists Wilmington, NC schmidtyvision@msn.com FINDACAR Family history IOP Nearsightedness Diabetes/Vascular
More informationPage 1. Robert P. Wooldridge, OD, FAAO
Robert P. Wooldridge, OD, FAAO I have received support from the following companies Alcon, Allergan, Biotissue, Centervue, EyeiC, Oculus, Optovue, Synemed, 46 yo WM referred as glaucoma suspect MH: no
More informationEast and North Hertfordshire treatment pathway for primary open angle glaucoma and ocular hypertension in adults
East and North Hertfordshire treatment pathway for primary open angle glaucoma and ocular hypertension in adults Introduction Glaucoma is a group of eye diseases causing optic nerve damage. In most cases
More informationTargeting Intraocular Pressure in Glaucoma: a Teaching Case Report 1
Targeting Intraocular Pressure in Glaucoma: a Teaching Case Report 1 By: Andrew Kemp, OD, Marcus Gonzales, OD, FAAO, Joe DeLoach, OD, FAAO, and Zanna Kruoch, OD FAAO Background Glaucoma is a range of conditions
More informationGoals. Glaucoma PARA PEARL TO DO. Vision Loss with Glaucoma
Glaucoma Janet R. Fett, OD Drs. Kincaid, Fett and Tharp So Sioux City, NE eyewear21@hotmail.com Goals Understand Glaucoma Disease process Understand how your data (objective and subjective) assists in
More informationPRACTICAL APPROACH TO MEDICAL MANAGEMENT OF GLAUCOMA
PRACTICAL APPROACH TO MEDICAL MANAGEMENT OF GLAUCOMA DR. RAVI THOMAS, DR. RAJUL PARIKH, DR. SHEFALI PARIKH IJO MAY 2008 PRESENTER AT JDOS : DR. RAHUL SHUKLA T.N. SHUKLA EYE HOSPITAL TERMINOLOGY POAG: PRIMARY
More informationElevated intraocular pressure (IOP) is a major risk factor for
Glaucoma Twenty-Four Hour Pattern of Intraocular Pressure in Untreated Patients with Ocular Hypertension Tomas M. Grippo, 1,2 John H. K. Liu, 1 Nazlee Zebardast, 2 Taylor B. Arnold, 3 Grant H. Moore, 1
More informationMicro-Invasive Glaucoma Surgery (Aqueous Stents)
Micro-Invasive Glaucoma Surgery (Aqueous Stents) Policy Number: Original Effective Date: MM.06.029 02/01/2019 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 02/01/2019 Section:
More informationThe Use of SLT in Secondary Open Angle Glaucomas ( PEXG, PDG)
The Use of SLT in Secondary Open Angle Glaucomas ( PEXG, PDG) Prof. S. Melamed The Sam Rothberg Glaucoma Center Tel Aviv University Medical School Israel Wear and Tear Glaucoma * Particulate Matter Glaucoma
More informationMessages From the Advanced Glaucoma Intervention Study
Landmark Studies Section editor: Ronald L. Fellman, MD Take-Home Messages From the Advanced Glaucoma Intervention Study By Leon W. Herndon, MD, and Daniel B. Moore, MD I tasked Leon W. Herndon, MD, and
More informationCentral corneal thickness and vascular risk factors in normal tension glaucoma
Central corneal thickness and vascular risk factors in normal tension glaucoma Aoife Doyle, Ahmed Bensaid and Yves Lachkar L Institut du Glaucome, Fondation Hoˆpital St. Joseph, Paris, France ABSTRACT.
More informationVisual field progression outcomes in glaucoma subtypes
Visual field progression outcomes in glaucoma subtypes Carlos Gustavo De Moraes, 1,2,3 Jeffrey M. Liebmann, 1,2 Craig A. Liebmann, 1 Remo Susanna Jr, 3 Celso Tello 1,4 and Robert Ritch 1,4 1 Einhorn Clinical
More informationGlaucoma Clinical Update. Barry Emara MD FRCS(C) Giovanni Caboto Club October 3, 2012
Glaucoma Clinical Update Barry Emara MD FRCS(C) Giovanni Caboto Club October 3, 2012 Objectives Understand the different categories of glaucoma Recognize the symptoms and signs of open angle and angle-closure
More informationFROM OUTDATED TO UPDATED Eminence-Based Medicine
FROM OUTDATED TO UPDATED Eminence-Based Medicine Evidence-Based Medicine A REVIEW OF KEY CLINICAL TRIALS Anthony DeWilde, OD FAAO 1 EMINENCE BASED MEDICINE 2 EVIDENCE BASED MEDICINE 3 4 CLINICAL TRIALS
More informationGlaucoma. Glaucoma. Optic Disc Cupping
Glaucoma What is Glaucoma? Bruce James A group of diseases in which damage to the optic nerve occurs as a result of intraocualar pressure being above the physiological norm for that eye Stoke Mandeville
More informationMicro-Invasive Glaucoma Surgery (Aqueous Stents)
Micro-Invasive Glaucoma Surgery (Aqueous Stents) Policy Number: Original Effective Date: MM.06.029 02/01/2019 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 02/01/2019 Section:
More informationThe second most common causes of blindness worldwide. ( after cataract) The commonest cause of irreversible blindness in the world Estimated that 3%
The second most common causes of blindness worldwide. ( after cataract) The commonest cause of irreversible blindness in the world Estimated that 3% of our population age > 40 have glaucoma In the past:
More informationSelective Laser Trabeculoplasty (SLT): When and How BRIAN A. FRANCIS, MD, MS
Selective Laser Trabeculoplasty (SLT): When and How BRIAN A. FRANCIS, MD, MS RIFFENBURGH PROFESSOR OF GLAUCOMA DOHENY EYE INSTITUTE KECK SCHOOL OF MEDICINE UNIVERSITY OF SOUTHERN CALIFORNIA 1 Key Topics
More information1/31/2018. Course Objectives. Diagnostic Testing. Optic Nerve Damage ANATOMY AND PHYSIOLOGY OF A GLAUCOMA WORK-UP/TONOMETRY TECHNICIAN: -SDP
ANATOMY AND PHYSIOLOGY OF A GLAUCOMA WORK-UP/TONOMETRY KNOW THE DISEASE PROCESS TECHNICIAN: EXPLAIN PROCESS OF EXAMINATION Presenters: Dana McMahan, COA Nicole Smith, COA Engage with patient s, help alleviate
More informationTHE CHRONIC GLAUCOMAS
THE CHRONIC GLAUCOMAS WHAT IS GLAUCOMA? People with glaucoma have lost some of their field of all round vision. It is often the edge or periphery that is lost. That is why the condition can be missed until
More informationTHE CHRONIC GLAUCOMAS
THE CHRONIC GLAUCOMAS WHAT IS GLAUCOMA People with glaucoma have lost some of their field of all round vision. It is often the edge or periphery that is lost. That is why the condition can be missed until
More informationDivakar Gupta Glaucoma Fellow, Duke Eye Center 5/14/16
Divakar Gupta Glaucoma Fellow, Duke Eye Center 5/14/16 Pathophysiology of glaucoma Consider risk factors of glaucoma Understand the side effects of glaucoma medications Diagnostic testing Leading cause
More informationEfficacy and Tolerability of Latanoprost 0.005% in Treatment of Primary Open Angle Glaucoma (POAG)
Original Article Efficacy and Tolerability of Latanoprost.5% in Treatment of Primary Open Angle Glaucoma (POAG) Muhammad Imran Janjua, Saira Bano, Ali Raza Pak J Ophthalmol 217, Vol. 33, No. 3.....................................................................................................
More information11/30/2009. Glaukosis: ancient greek term meaning sparkling or shining appearance of pupil
Normal Ocular Anatomy Glaucoma Dr Sunil Deokule, MD Asst. Prof and Glaucoma Specialist University of Kentucky Definition Glaukosis: ancient greek term meaning sparkling or shining appearance of pupil Optic
More informationClinical Discussions in Glaucoma
Clinical Discussions in Glaucoma Joseph W. Sowka, OD, FAAO, Diplomate Professor of Optometry Nova Southeastern University, College of Optometry 3200 South University Drive Fort Lauderdale, Florida 33328
More informationConsiderations in the Cataract Patient with Glaucoma. Robert Noecker, MD, MBA Ophthalmic Consultants of Connecticut Fairfield, CT
Considerations in the Cataract Patient with Glaucoma Robert Noecker, MD, MBA Ophthalmic Consultants of Connecticut Fairfield, CT Financial Disclosure Dr. Noecker has been a paid consultant to Allergan,
More informationContents Optic Nerve: The Glaucomatous Optic Nerve Optic Nerve: Clinical Examination Optic Nerve: Heidelberg Retinal Tomography
Contents 1 Optic Nerve: The Glaucomatous Optic Nerve................... 1 1.1 Why Is the Optic Nerve Important in the Diagnosis and Management of Glaucoma?............................ 1 References.................................................
More information24-h Efficacy of Glaucoma Treatment Options
Adv Ther (2016) 33:481 517 DOI 10.1007/s12325-016-0302-0 REVIEW 24-h Efficacy of Glaucoma Treatment Options Anastasios G. P. Konstas. Luciano Quaranta. Banu Bozkurt. Andreas Katsanos. Julian Garcia-Feijoo.
More informationWritten by Administrator Wednesday, 13 January :27 - Last Updated Thursday, 21 January :34
angle closure glaucoma A type of glaucoma caused by a sudden and severe rise in eye pressure. Occurs when the pupil enlarges too much or too quickly, and the outer edge of the iris blocks the eye s drainage
More informationGlaucoma Evaluation. OCT Pearls for Glaucoma. OCT: Retinal Nerve Fiber Layer. Financial Disclosures. OCT: Macula. Case Example
OCT Pearls for Glaucoma using OCT of the macula for glaucoma Glaucoma Evaluation Right eye Visual Acuity 20/25 20/25 IOP 13 13 Central corneal 530 530 thickness Anterior exam Normal with PCIOL Normal with
More informationWGA. The Global Glaucoma Network
The Global Glaucoma Network Fort Lauderdale April 30, 2005 Indications for Surgery 1. The decision for surgery should consider the risk/benefit ratio. Note: Although a lower IOP is generally considered
More information9/25/2017 CASE. 67 years old On 2 topical meds since 3 years. Rx: +3.0 RE LE
CASE 67 years old On 2 topical meds since 3 years Rx: +3.0 /-0.5@65 RE +2.5/-0.5@115 LE IOP : 17 RE 19 LE CD: 0.5 RE 0.6 LE 1 67 years old On 2 topical meds since 3 years Rx: +3.0 /-0.5@65 RE +2.5/-0.5@115
More information24-hour IOP fluctuation: myth or reality?
Journal for Modeling in Ophthalmology 2016; 2:103-109 Review article 24-hour IOP fluctuation: myth or reality? Luciano Quaranta 1, Ivano Riva 1, Francesco Oddone 2 1 Department of Medical and Surgical
More informationEffects of Argon Laser Trabeculoplasty in the Early Manifest Glaucoma Trial. Heijl, Anders; Peters, Dorothea; Leske, M Christina; Bengtsson, Boel
Effects of Argon Laser Trabeculoplasty in the Early Manifest Glaucoma Trial. Heijl, Anders; Peters, Dorothea; Leske, M Christina; Bengtsson, Boel Published in: American Journal of Ophthalmology DOI: 10.1016/j.ajo.2011.04.036
More informationSpontaneous Intraocular Pressure Reduction in Normal-Tension Glaucoma and Associated Clinical Factors
CLINICAL INVESTIGATIONS Spontaneous Intraocular Pressure Reduction in Normal-Tension Glaucoma and Associated Clinical Factors Akihiro Oguri, Tetsuya Yamamoto and Yoshiaki Kitazawa Department of Ophthalmology,
More information24-hour Intraocular Pressure and Ocular Perfusion Pressure in Glaucoma
SURVEY OF OPHTHALMOLOGY VOLUME 58 NUMBER 1 JANUARY FEBRUARY 2013 MAJOR REVIEW 24-hour Intraocular Pressure and Ocular Perfusion Pressure in Glaucoma Luciano Quaranta, MD, PhD, 1 Andreas Katsanos, MD, PhD,
More informationCentral corneal thickness among glaucoma patients attending Menelik II Hospital, Addis Ababa, Ethiopia
Original article Central corneal thickness among glaucoma patients attending Menelik II Hospital, Addis Ababa, Ethiopia Zelalem Gizachew 1, Abiy Mulugeta 1* Abstract Background: Glaucoma is one of the
More informationResearch Article Long-Term Clinical Course of Normal-Tension Glaucoma: 20 Years of Experience
Hindawi Ophthalmology Volume 2017, Article ID 2651645, 6 pages https://doi.org/10.1155/2017/2651645 Research Article Long-Term Clinical Course of Normal-Tension Glaucoma: 20 Years of Experience Sang Wook
More informationCentral Corneal Thickness-An important variable for prognostication in Primary Open Angle glaucoma; A Kolkata based study in Eastern India
Original article: Central Corneal Thickness-An important variable for prognostication in Primary Open Angle glaucoma; A Kolkata based study in Eastern India 1Dr. Apala Bhattacharya, 2 Dr Gautam Bhaduri,
More informationGlaucoma. How is Glaucoma Diagnosed? Glaucoma Testing
Glaucoma How is Glaucoma Diagnosed? Glaucoma Testing There is no single test for glaucoma. The diagnosis is made by evaluating the patient from a number of perspectives, using specialized instruments.
More informationVisit Type (Check one)
Page 1 of 14 OHFV21.01 MULE: Page 1 Visit Type (Check one) Visit prior to 078 month visit enter visit window 0 Semi-Annual: Annual: 078 mo. 090 mo. 102 mo. 114 mo. 126 mo. 138 mo. 150 mo. 162 mo. 084 mo.
More informationIntraocular pressure (IOP) is the main risk factor for the
The Circadian Curve of Intraocular Pressure: Can We Estimate Its Characteristics during Office Hours? Paolo Fogagnolo, 1 Nicola Orzalesi, 2 Antonio Ferreras, 3,4 and Luca Rossetti 2 PURPOSE. To verify
More informationUnderstanding Angle Closure
Case Understanding Angle Closure Dominick L. Opitz, OD, FAAO Associate Professor Illinois College of Optometry 56 year old Caucasian Male Primary Eye Exam BCVA: 20/25 OD with+1.25 DS 20/25 OS with +1.75
More informationSTARTING IN THE 1960s, epidemiological. Reduction of Intraocular Pressure and Glaucoma Progression. Results From the Early Manifest Glaucoma Trial
CLINICAL SCIENCES Reduction of Intraocular Pressure and Glaucoma Progression Results From the Early Manifest Glaucoma Trial Anders Heijl, MD, PhD; M. Cristina Leske, MD, MPH; Bo Bengtsson, MD, PhD; Leslie
More informationVI.2.2 Summary of treatment benefits
EU-Risk Management Plan for Bimatoprost V01 aetiology), both OAG and ACG can be secondary conditions. Secondary glaucoma refers to any case in which another disorder (e.g. injury, inflammation, vascular
More informationInternational Journal of Health Sciences and Research ISSN:
International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article Conversion of Ocular Hypertensives into Glaucoma: A Retrospective Study Aditi Singh 1, Shibi
More informationLearn Connect Succeed. JCAHPO Regional Meetings 2016
Learn Connect Succeed JCAHPO Regional Meetings 16 Number of patients Number of eyes 1/18/16 Medication Adherence in Glaucoma: An Update Financial Disclosure The speaker has the following relevant financial
More informationGlaucoma For The Everyday Optometrist
A Review Of Risk Factors Glaucoma For The Everyday Optometrist Eric E. Schmidt, O.D., F.A.A.O. Omni Eye Specialists Wilmington, NC schmidtyvision@msn.com FINDACAR Family history IOP Nearsightedness Diabetes/Vascular
More informationEndocyclophotodestruction in Glaucoma Patients Undergoing Combined Surgery of Pars Plana Vitrectomy and Phacoemulsification
e-issn 643-370 DOI: 0.269/MSM.89097 Received: 204.04.23 Accepted: 204.0.29 Published: 204.0. Endocyclophotodestruction in Glaucoma Patients Undergoing Combined Surgery of Pars Plana Vitrectomy and Phacoemulsification
More informationPrevalence Of Primary Open Angle Glaucoma in Diabetic Patients
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 16, Issue 6 Ver. III (June. 2017), PP 147-151 www.iosrjournals.org Prevalence Of Primary Open Angle Glaucoma
More informationCorrelating central corneal thickness and intraocular pressure in ocular hypertension and glaucoma
VOL. 3 NO. 1 PHILIPPINE JOURNAL OF Ophthalmology JANUARY ORIGINAL ARTICLE JUNE 07 Jonathan G. Soriano, MD 1 Ma. Margarita L. Lat-Luna, MD 1, 3 Patricia M. Khu, MD 1, 1 Department of Ophthalmology and Visual
More informationThe Optic Nerve Head In Glaucoma. Clinical Pearl #1. Characteristics of Normal Disk 9/26/2017. Initial detectable damage Structure vs function
The Optic Nerve Head In Glaucoma Clinical Pearl #1 Eric E. Schmidt, O.D., F.A.A.O. Omni Eye Specialists Wilmington,NC schmidtyvision@msn.com Glaucoma is an optic neuropathy Initial detectable damage Structure
More informationCentral corneal thickness and normal tension glaucoma: A cross-sectional study
Optometry (2006) 77, 134-140 Central corneal thickness and normal tension glaucoma: A cross-sectional study Michael Sullivan-Mee, O.D., a Kathy D. Halverson, O.D., a Mollie C. Saxon, O.D., a Glenn B. Saxon,
More informationManagement of Angle Closure Glaucoma Hospital Authority Convention 18 May 2015
Management of Angle Closure Glaucoma Hospital Authority Convention 18 May 2015 Jimmy Lai Clinical Professor Department of Ophthalmology The University of Hong Kong 1 Primary Angle Closure Glaucoma PACG
More informationTRABECULECTOMY THE BEST AND WORST CANDIDATES
TRABECULECTOMY THE BEST AND WORST CANDIDATES MICHAEL F. OATS, MD OPHTHALMIC CONSULTANTS OF BOSTON ASCRS 2014 FINANCIAL DISCLOSURES None TRABECULECTOMY Performed for over 100 years Most commonly performed
More informationTreatments on the Horizon
Latanoprostene bunod (Vesneo) Treatments on the Horizon Dominick L Opitz, OD, FAAO Associate Professor Illinois College of Optometry Valeant (B+L) Nitrous oxide-donating prostaglandin F2-alpha analogue
More informationThe innovative aspects are that ORA G3 is currently the only device capable of measuring corneal hysteresis.
pat hways ORA G3 to measure corneal hysteresis Medtech innovation briefing Published: 18 June 2018 nice.org.uk/guidance/mib150 Summary The technology described in this briefing is Ocular Response Analyzer
More informationEndo Optiks. Clinical Publication Summaries
Endo Optiks Clinical Publication Summaries Effective. Safe. Simple. Four scientific studies demonstrating the proven clinical benefits of combined ECP and cataract surgery. ECP is an Effective, Safe, and
More informationA LITTLE ANATOMY. three layers of eye: 1. outer: corneosclera. 2. middle - uvea. anterior - iris,ciliary body. posterior - choroid
GLAUCOMA A LITTLE ANATOMY three layers of eye: 1. outer: corneosclera 2. middle - uvea anterior - iris,ciliary body posterior - choroid connection at the pars plana between post and ant uvea 3. retina
More information3/23/2016. Regina Smolyak, MD Glaucoma Service Flaum Eye Institute
Under the Affordable Care Act providers are pressured to maintain a high level of medical care, while reducing the cost of the treatment delivered Regina Smolyak, MD Glaucoma Service Flaum Eye Institute
More informationANSWERS TO YOUR MOST COMMON GLAUCOMA QUESTIONS
For Your Eyes Only: ANSWERS TO YOUR MOST COMMON GLAUCOMA QUESTIONS www.kremereyecenter.com / 800-694-3937 1 Table of Contents Introduction... 3 Glaucoma Defined... 4 Symptoms of Glaucoma... 6 Treatment
More informationIOP measurements: 8.00 am (trough drug levels) and am (peak drug levels)(2 hours post dose)
This overview of 2% eye drops was presented by Dr. Ravin N. Das, at Hotel Satya Ashoka, on 19-6-2004 in place of Dr. H. S. Ray due to unforseen circumstances. This dinner meeting was sponsored by Cipla
More informationCurrent Therapy in Ocular Disease -The Vision Institute of Canada-
Current Therapy in Ocular Disease -The Vision Institute of Canada- Separating the Good, the Bad and the Ugly: Is It Glaucoma or Not Reducing the Pressure on Glaucoma Decision-Making Update and Clinical
More informationGLAUCOMA SURGERY: FROM THEN TIL NOW (COPE Course ID: GL)
MIGS: How did we get here? GLAUCOMA SURGERY: FROM THEN TIL NOW (COPE Course ID: 55570-GL) John Gelvin, O.D., F.A.A.O. MOYES EYE CENTER Kansas City, Missouri jgelvin@moyeseye.com 1. Tube vs Trabeculectomy?
More informationGlaucoma Surgical Treatments. Murray Fingeret, OD Justin Schweitzer, OD Joe Sowka, OD
Glaucoma Surgical Treatments Murray Fingeret, OD Justin Schweitzer, OD Joe Sowka, OD Disclosures Murray Fingeret Consultant Bausch & Lomb, Alcon, Allergan Justin Schweitzer Allergan, Glaukos, Bausch and
More informationRole of central corneal thickness measurement in management of open angle glaucoma and glaucoma suspects in Calabar, Nigeria
Original Research Article Role of central corneal thickness measurement in management of open angle glaucoma and glaucoma suspects in Calabar, Nigeria Nkanga DG 1,2, Ibanga AA 1,2, Nkanga ED 2, Etim BA
More informationCorrespondence should be addressed to Brian A. Francis;
Hindawi Journal of Ophthalmology Volume 2017, Article ID 8248710, 9 pages https://doi.org/10.11/2017/8248710 Clinical Study Short-Term Clinical Results of Ab Interno Trabeculotomy Using the Trabectome
More informationGlaucoma is the most frequent
Refined glaucoma referral practice offers prospect of improved capacity and expanded role for primary eye care professionals BY ROD MCNEIL Glaucoma is the most frequent cause of irreversible blindness
More informationFinancial Disclosure. Prostaglandin Analogs (PGs) The Glaucoma Grab Bag: Practical Guidelines for Effective Glaucoma Therapy
The Glaucoma Grab Bag: Practical Guidelines for Effective Glaucoma Therapy Danica J. Marrelli, OD, FAAO University of Houston College of Optometry Financial Disclosure I have received I have received speaking
More informationIs this glaucoma? Leo Semes, OD Michael Chaglasian, OD Danica Marrelli, OD. Optometry s Meeting 2015 Seattle, WA
Is this glaucoma? Leo Semes, OD Michael Chaglasian, OD Danica Marrelli, OD Optometry s Meeting 2015 Seattle, WA Case 1. 54 WM Engineer is referred to UAB Eye Care as a glaucoma suspect. Mild myopic refractive
More informationThe Place for Selective Laser Trabeculoplasty in the Management of Glaucoma
The Place for Selective Laser Trabeculoplasty in the Management of Glaucoma Jung-Il Moon, M.D., PhD Glaucoma Services Catholic Eye Center St. Mary s s Hospital The Catholic Univ. of Korea Treatment of
More informationFinancial Disclosure. Visual Field Interpretation RELIABILITY VISUAL FIELD INTERPRETATION IN GLAUCOMA METHODS OF DATA PRESENTATION
VISUAL FIELD INTERPRETATION IN GLAUCOMA Danica J. Marrelli, OD, FAAO University of Houston College of Optometry Financial Disclosure I have received speaking and/or consulting fees from: Aerie Pharmaceutical
More informationCentral corneal thickness determined with optical coherence tomography in various types of glaucoma
Br J Ophthalmol 2000;84:1233 1237 1233 Department of Ophthalmology, Ludwig-Maximilians- University, Munich, Germany M Bechmann M J Thiel B Roesen S Ullrich M W Ulbig K Ludwig Correspondence to: Martin
More information10/3/2018. Case: 63 year old white female 6/11/2012 visit. Glaucoma Update for the Primary Care OD CHRISTOPHER WOLFE, OD, FAAO, DIPL ABO
DISCLOSURE STATEMENT Ihave no direct financial or proprietary interest in any companies, products or services mentioned in this presentation. GLAUCOMA UPDATE FOR THE PRIMARY CARE OD Please silence all
More informationDisclosures. What is glaucoma? Prevalence studies. Types of glaucoma 3/21/2016. Pinakin G Davey PhD, OD, FAAO. Professor and Director of Research
Disclosures Pinakin G Davey PhD, OD, FAAO Professor and Director of Research Principal investigator for ivue OCT trial Principal investigator Topcon FDA trials for Maestro and OCT 2000 Consultant for Topcon
More informationEfficacy of latanoprost in management of chronic angle closure glaucoma. Kumar S 1, Malik A 2 Singh M 3, Sood S 4. Abstract
Original article Efficacy of latanoprost in management of chronic angle closure glaucoma Kumar S 1, Malik A 2 Singh M 3, Sood S 4 1 Associate Professor, 2 Assistant Professor, 4 Professor, Department of
More information